Goldman Sachs Group Inc Bolt Biotherapeutics, Inc. Transaction History

Goldman Sachs Group Inc

  • $555 Billion
  • Q1 2024

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

May 14, 2024
BUY
$1.27 - $1.95 $1,377 - $2,115
1,085 Added 0.38%
284,170 $363,000
Q2 2023

Aug 14, 2023
BUY
$1.27 - $1.95 $1,377 - $2,115
1,085 Added 0.38%
284,170 $363,000
Q1 2023

May 14, 2024
BUY
$1.29 - $1.66 $73 - $94
57 Added 0.02%
283,085 $393,000
Q1 2023

May 11, 2023
BUY
$1.29 - $1.66 $73 - $94
57 Added 0.02%
283,085 $393,000
Q4 2022

May 14, 2024
BUY
$1.26 - $1.48 $341,312 - $400,906
270,883 Added 2230.41%
283,028 $367,000
Q4 2022

Feb 13, 2023
BUY
$1.26 - $1.48 $341,312 - $400,906
270,883 Added 2230.41%
283,028 $367,000
Q3 2022

May 14, 2024
SELL
$1.72 - $2.61 $37,179 - $56,417
-21,616 Reduced 64.03%
12,145 $18,000
Q3 2022

Nov 10, 2022
SELL
$1.72 - $2.61 $37,179 - $56,417
-21,616 Reduced 64.03%
12,145 $0
Q2 2022

May 14, 2024
BUY
$1.41 - $2.91 $47,603 - $98,244
33,761 New
33,761 $69,000
Q2 2022

Aug 15, 2022
SELL
$1.41 - $2.91 $17,644 - $36,415
-12,514 Reduced 27.04%
33,761 $69,000
Q1 2022

May 16, 2022
SELL
$2.74 - $4.82 $1.19 Million - $2.09 Million
-433,632 Reduced 90.36%
46,275 $126,000
Q4 2021

Feb 14, 2022
BUY
$4.19 - $13.97 $155,620 - $518,859
37,141 Added 8.39%
479,907 $2.35 Million
Q3 2021

Nov 10, 2021
BUY
$11.15 - $18.6 $4.94 Million - $8.24 Million
442,766 New
442,766 $5.6 Million

Others Institutions Holding BOLT

# of Institutions
40
Shares Held
24.3M
Call Options Held
0
Put Options Held
0
View Full List

About Bolt Biotherapeutics, Inc.

BOLT Quotes by TradingView
  • Ticker BOLT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,641,500
  • Market Cap $28.2M
  • Description
  • Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-e...
More about BOLT
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email